Clarivate Plc (CLVT) is a global provider of transformative intelligence, supporting the innovation lifecycle from idea generation to intellectual property protection. The company offers enriched data, insights, analytics, workflow solutions, and expert services to help customers discover, protect, and commercialize new ideas. Its solutions cater to a diverse global customer base, including academic institutions, corporations, and healthcare organizations, with a focus on subscription-based and re-occurring revenue models.
- Academia & Government (A&G) - Provides data, insights, and workflow solutions to academic institutions and government organizations, enabling research, funding, and policy-making activities.
- Intellectual Property (IP) - Offers tools and services for managing and protecting intellectual property assets, including patent and trademark maintenance and analytics.
- Life Sciences & Healthcare (LS&H) - Delivers insights and tools to accelerate drug development, improve healthcare innovation, and support life sciences research.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Bar Veinstein Executive | President, Academia & Government | Bar Veinstein joined Clarivate in April 2023 as President, Academia & Government. He brings over 25 years of global leadership experience, previously serving as CEO of Taranis and President of Ex Libris Group. | ||
Gordon Samson Executive | President, Intellectual Property | Gordon Samson has been serving as President, Intellectual Property at Clarivate since April 2023, joining the company in October 2020 through the acquisition of CPA Global. He brings over 30 years of experience in senior executive roles, having previously contributed significantly at companies like CPA Global and Williams Lea. | ||
Henry Levy Executive | President, Life Sciences & Healthcare | Henry Levy has over 30 years of experience in the life sciences and healthcare sectors and joined Clarivate in May 2023 as President, Life Sciences & Healthcare. He previously served as Chief Strategy Officer and held other senior roles at Veeva Systems Inc., Chief Commercial Officer at PPD, Inc., and led Accenture plc's global life sciences R&D practice. | ||
Jonathan Collins Executive | Executive Vice President and Chief Financial Officer | Jonathan Collins is the Executive Vice President and Chief Financial Officer (CFO) of Clarivate (CLVT) since December 2021, overseeing the global financial organization and fiscal strategies. Previously, he held key financial leadership roles at Dana Incorporated and ProQuest. | ||
Matti Shem Tov Executive | Chief Executive Officer | CEO of Clarivate since August 9, 2024 , with over 30 years of global leadership experience including previous CEO roles at ProQuest LLC (September 2017 to June 2022) and leadership at Ex Libris Ltd.. | View Report → | |
William Graff Executive | Executive Vice President and Chief Information Officer | William Graff has served as Executive Vice President and Chief Information Officer at CLVT since February 2022, bringing over 35 years of technology leadership experience. Previously, he was the Chief Information Officer at Oracle Cerner. | ||
Adam T. Levyn Board | Independent Director | Partner at Leonard Green & Partners (since 2011); Board member at Advantage Solutions, Inc. (since October 2023); Board member at CHG Healthcare Services; Board member at ExamWorks Group, Inc.; Board member at HUB International Limited; Board member at OMNIA Partners, Inc.; Board member at Parts Town LLC; Board member at Service Logic LLC | Adam T. Levyn has served as an Independent Director at Clarivate Plc since October 2020. He brings extensive experience from his active role as a Partner at Leonard Green & Partners since 2011 and from his previous positions at KKR and Bear, Stearns. | |
Andrew Snyder Board | Non-Executive Board Chair | CEO of Cambridge Information Group; New York-Presbyterian Board of Trustees; Board of Advisors of Penn Libraries | Andrew Snyder joined Clarivate as a director in December 2021 and assumed the role of Non-Executive Board Chair in October 2022, playing a key role in strategic board oversight. He is also the CEO of Cambridge Information Group since 2003, reflecting his extensive leadership in the investment and information services sectors. | |
Anthony Munk Board | Director | Vice Chairman of Onex Corporation; Chair of Onex Partners’ Private Equity Investment Committee; Director at Emerald Holding, Inc. | Anthony Munk has been a Director at Clarivate since May 2019. He serves on the Audit and Finance Committees and is recognized for his financial expertise and strategic experience. | |
Jane Okun Bomba Board | Director | Director, Brightview Holdings, Inc. since April 2019; Board Member, Aspire Healthy Energy; Board Member, Kickstart International; Member, University of Michigan, Ross School of Business Dean’s Advisory Board | Jane Okun Bomba has served as an independent director on the Clarivate Board of Directors since May 2020. She is the Chair of the Human Resources and Compensation Committee and a member of the Audit Committee, leveraging extensive experience in human resources, finance, sustainability/ESG, and investor relations. | |
Saurabh Saha Board | Director | CEO of Centessa Pharmaceuticals plc; Board Member at Centessa Pharmaceuticals plc | Saurabh Saha has been a Director at Clarivate (CLVT) since May 2023 and serves on both the Human Resources and Compensation and the Risk and Sustainability committees. He brings over 20 years of health and life sciences experience and is currently the CEO and a board member at Centessa Pharmaceuticals plc since January 2021. | |
Suzanne Heywood Board | Director | COO of Exor N.V. (since November 2022); Chair of CNHi Industrial N.V. (since 2018); Chair of Iveco Group N.V. (since 2022); Board member of The Economist Group; Board member of Christian Louboutin LLC; Board member of Shang Xia; Board member of Quartz Associates; Board member of Heywood Foundation | Suzanne Heywood has been a Director at Clarivate since May 2024 and serves on the Nominating & Governance and Finance Committees, bringing extensive global experience in finance and strategic matters from her roles as COO of Exor N.V. and various board positions. | |
Usama N. Cortas Board | Director | Board member at Convergint; Board member at ECI Software Solutions; Board member at Jetro Cash & Carry; Board member at Iris Software Group; Board member at Insight Global; Board member at Prometheus Group | Usama N. Cortas has been an independent Director at Clarivate since October 2020, serving on the Nominating & Governance Committee and as Chair of the Finance Committee. Previously, he was a Partner at Leonard Green & Partners since 2003 and worked in investment banking at Morgan Stanley from 2000 to 2003. | |
Valeria Alberola Board | Member of the Board of Directors | Valeria Alberola has served on the Board of Directors at CLVT since May 2021, acting as Chair of the Audit Committee and member of the Finance Committee. With over 25 years of global experience in corporate finance and strategic management, she previously held executive roles such as CEO of Zoma Holdings and CFO of Bridge Education Group. | ||
Wendell Pritchett Board | Director | Toll Brothers, Inc. Director (since March 2018); 26North BDC, Inc. Director (since February 2024); Chair of the Board of Trustees of College Unbound; Board member of the Philadelphia Foundation; Board member of LifePoint Health; Board member of Forman Arts Initiative; Board member of Reinvestment Fund | Wendell Pritchett, Ph.D., has been a Director at Clarivate since July 2022 and serves on the Nominating & Governance, Human Resources & Compensation, and Risk & Sustainability Committees. He has extensive experience in academia and public service, holding multiple leadership and board roles outside of Clarivate. |
- Considering the clear uptick in AI-related patent filings, how does management plan to capitalize on this growth while addressing the apparent regional imbalance, particularly in China?
- With the Department of Commerce considering changes to the U.S. patent fee structure, what specific measures is management taking to mitigate potential negative impacts on the IP annuity market?
- Given the described delays in disposals, particularly for one-time e-book transactions, how is management adjusting its customer engagement strategy to minimize prolonged transition periods?
- The sales incentive plan’s refocus on subscription and recurring revenue has been highlighted; what tangible improvements are you seeing in sales execution, and how sustainable is this momentum into the next fiscal period?
- Despite favorable renewal rates, universities are facing funding cuts; how is management planning to address potential disruptions in renewal cycles while maintaining high retention levels in the A and G segment?
Research analysts who have asked questions during CLARIVATE earnings calls.
George Tong
Goldman Sachs
5 questions for CLVT
Manav Patnaik
Barclays
4 questions for CLVT
Owen Lau
Oppenheimer & Co. Inc.
3 questions for CLVT
Shlomo Rosenbaum
Stifel, Nicolaus & Company, Incorporated
3 questions for CLVT
Surinder Thind
Jefferies Financial Group
3 questions for CLVT
Toni Kaplan
Morgan Stanley
3 questions for CLVT
Adam Parrington
Stifel Financial Corp.
2 questions for CLVT
Andrew Nicholas
William Blair & Company
2 questions for CLVT
Ashish Sabadra
RBC Capital Markets
2 questions for CLVT
Peter Christiansen
Citigroup Inc.
2 questions for CLVT
William Qi
RBC Capital Markets
2 questions for CLVT
David Paige Papadogonas
RBC Capital Markets
1 question for CLVT
Gregory Parrish
Morgan Stanley
1 question for CLVT
Guru Sidaarth
Oppenheimer & Co. Inc.
1 question for CLVT
Kwun Sum Lau
Oppenheimer
1 question for CLVT
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Global QMS, Inc. (Global Q) | 2024 | Clarivate’s acquisition of Global Q added cloud-based regulatory and compliance management solutions, including its flagship SaaS platform Optiqs360 Digital™ and tools like MediGPT - WorkCenter™ and MediGPT - IntelliWriter™, to bolster its life sciences and supply chain capabilities; financial terms were not disclosed. |
ProQuest | 2021 | The ProQuest acquisition was completed for a total of $5.3 billion via approximately $4.0 billion in cash and $1.3 billion in equity, strategically expanding Clarivate’s research intelligence services and enhancing revenue and cost synergies while also resulting in board changes. |
CPA Global | 2020 | Completed as a cash and stock transaction on October 1, 2020, this deal had an aggregate consideration of approximately $8.7 million (net adjustments applied) and involved issuing over 216 million ordinary shares to create a strong global intellectual property platform, including significant debt repayment and board expansion initiatives. |
Recent press releases and 8-K filings for CLVT.
- Claritev Corporation (NYSE: CTEV) and iO Health-FZE have announced a strategic agreement to introduce iO Health's Optima AI platform to the Middle East and North Africa (MENA) region.
- Claritev has secured exclusive rights to license, integrate, and resell the AI-powered revenue cycle management solution in MENA.
- Optima AI is designed to streamline financial and administrative processes for healthcare providers, aiming to reduce claim denials, optimize workflows, and improve financial outcomes.
- This partnership is considered a pivotal step in Claritev's global expansion strategy.
- Clarivate is executing its Value Creation Plan, transitioning its revenue mix from transactional to subscription models, with 88% of the business currently subscription-based and a target of 90% over time.
- The company is significantly investing in product innovation, particularly in AI, by integrating AI into existing products and launching new "born AI" solutions like Web of Science Research Intelligence, which is set for general availability in May 2026.
- Clarivate aims to achieve market growth rates for organic revenue across its segments, with targets such as 3-4% for Academic & Government and 4-5% for Intellectual Property.
- EBITDA margins are projected to contract to 41% this year due to disposals and investments, but are expected to improve next year. The company also plans to reduce net leverage from approximately 4x to below 3x over the next few years, balancing debt paydown and share buybacks.
- Clarivate is progressing with its Value Creation Plan, aiming to increase its subscription business from 88% to 90% by phasing out transactional products like print books and real-world data brokering by mid-2026 and end of 2026, respectively.
- The company is heavily investing in product innovation, particularly in AI, with a dedicated center of excellence and new AI-enabled offerings such as Web of Science Research Intelligence, which is slated for general availability by May 2026.
- Clarivate is conducting a strategic review of non-core assets to create shareholder value, with findings anticipated by February 2026.
- For 2025, Clarivate guides for EBITDA margins of 41%, a 50 bps contraction due to disposals and investments, but expects future margin expansion and aims to reduce net leverage below 3x over time.
- Clarivate is executing its Value Creation Plan, transitioning its business from transactional to subscription models, with 88% of revenue now subscription-based, aiming for 90% over time. This includes phasing out transactional print books and e-books by June 2026 and the real-world data brokering business by the end of 2026.
- The company is investing in product innovation, particularly in AI, with new "born AI" products like MacRisk and Web of Science Research Intelligence. Web of Science Research Intelligence, an AI-enabled interactive platform, is expected to be generally available in May 2026.
- Clarivate aims to achieve market growth rates for organic revenue, which are estimated at 3-4% for A&G and 4-5% for IP.
- For the current year, EBITDA margins are guided to contract by 50 basis points to 41% due to disposals and investments, but the company expects margin expansion in the future as disposals conclude and organic growth improves.
- Clarivate's gross leverage is 4.3x, with a goal to reduce net leverage below 3 turns over time, balancing debt paydown and share buybacks.
- Clarivate's Value Creation Plan has successfully transitioned 88% of its business to a subscription basis, up from 80%, with a target of 90% over time, by phasing out transactional sales in Academic & Government and Life Science segments.
- The company is heavily investing in AI innovation, AI-enabling existing products and launching new "born AI" solutions, such as Web of Science Research Intelligence, which is expected to be generally available in May 2026.
- Clarivate aims to achieve market growth rates for organic revenue, targeting 3-4% for Academic & Government and 4-5% for Intellectual Property.
- For 2025, Clarivate projects EBITDA margins to contract by 50 basis points to 41%, but expects improvement post-disposals and with organic growth, anticipating 0.5-1 percentage point improvement from disposals.
- The company's capital allocation strategy balances debt paydown and share buybacks, with $100 million in shares repurchased in H1, and a long-term goal to reduce net leverage from ~4 turns to below three turns.
- Clarivate is progressing with the strategic review of its IP business divestiture, with an outcome anticipated to be communicated with year-end results in February.
- The company's Value Creation Plan is on track, with the recurring revenue mix reaching 88% (excluding disposals) in the first half of the year, and a goal to increase it towards 90%.
- Clarivate reported a 1.5% growth in its patent and trademark annuity business in the first half of 2025, and expects long-term growth for this segment in the 3% to 5% range, partly driven by increased AI innovation.
- AI integration is a key focus, with 4,800 academic institutions currently utilizing Clarivate's AI solutions, and new AI-powered products, such as Derwent Patent Watch, being introduced across segments.
- The capital allocation strategy currently prioritizes share repurchases and debt reduction, with M&A not being a focus during the ongoing strategic review.
- Clarivate Plc released a new "Companies to Watch" report on June 16, 2025, highlighting Radioligand Innovators in precision oncology.
- The report focuses on radioligand therapies (RLTs), a rapidly evolving class of therapeutics for cancer, and profiles emerging innovators such as Affibody, Alpha-9 Oncology, and Perspective Therapeutics.
- Notable market developments include Bristol Myers Squibb's $4.1 billion acquisition of RayzeBio and AstraZeneca's $2.4 billion acquisition of Fusion Pharmaceuticals, with the global radiopharmaceutical market projected to exceed $13 billion within the next decade.
- Clarivate Plc completed an incremental upsize of its term loan B credit facility on June 2, 2025.
- The company incurred a new $500 million tranche of incremental term loans maturing in 2031 with an interest rate margin of 325 basis points per annum.
- The proceeds from the new term loans were used to redeem $500 million aggregate principal amount of the outstanding 4.50% senior secured notes due 2026.
- After this partial redemption, $200 million aggregate principal amount of the 2026 notes remain outstanding, effectively extending the majority of their 2026 debt maturity.